Clinical trials: Androgenetic Alopecia
Androgenetic Alopecia
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
- Trial name
- NCT06118866
- Testing
- HMI-115-120mg-Q4W, HMI-115-240mg-Q4W, HMI-115, 240mg-Q2W
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd
Alopecia
AVODART® Alopecia Post-marketing Surveillance (PMS)
Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients
- Trial name
- AVODART®PMS (NCT01004809)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 712 people
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia
Adipose-derived SVF for Treatment of Alopecia
The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.
- Trial name
- NCT02626780
- Testing
- GID SVF-2
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GID BIO, Inc.
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Telogen Effluvium, Androgenetic Alopecia
Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.
The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia…
- Trial name
- NCT07433933
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Alopecia
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
- Trial name
- NCT02781311
- Testing
- Setipiprant, Finasteride
- Where
- 18 sites in United States
- Volunteers
- 169 people
- Sponsor
- Allergan
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Androgenic Alopecia, Alopecia
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia.
- Conditions
- Androgenic Alopecia, Alopecia, Baldness
- Trial name
- NCT07107841
- Testing
- Autologous Hair Follicle-Derived Secretome
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorn Biolabs Inc.
Androgenetic Alopecia
Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)
A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.
- Trial name
- NCT00396175
- Testing
- MK0906, finasteride / Duration of Treatment : 48 Weeks
- Volunteers
- 355 people
- Sponsor
- Organon and Co
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
- Conditions
- Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
- Trial name
- NCT06501924
- Testing
- DA-005, Topical minoxidil 5%, DA-002
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia
- Trial name
- NCT01686295
- Testing
- iRestore Hair Rejuvenation System
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 12 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 12 beam model for androgenetic alopecia in females when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT01016964
- Testing
- HairMax LaserComb 2009 model 12 beam
- Where
- 3 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia
Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss
HCap Formula is composed of medicinal plants, vitamins and minerals. The purpose of this study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair growth in men with tendencies for hair loss.
- Trial name
- NCT02150187
- Testing
- HCap Formula
- Where
- Israel
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Family Marketing
Androgenetic Alopecia, AGA
Safety and Efficacy of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06972264
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Male Pattern Baldness, Androgenetic Alopecia
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss
The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study.
- Conditions
- Male Pattern Baldness, Androgenetic Alopecia, Hair Loss/Baldness, Hair Loss
- Trial name
- CS-SAGA-001 (NCT05970809)
- Testing
- SAGA-001 (A), SAGA-001 (B)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 82 people
- Sponsor
- StimuSIL
Androgenetic Alopecia
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss.
- Trial name
- NCT00151515
- Testing
- minoxidil
- Where
- 15 sites in United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Alopecia
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido.
- Trial name
- NCT02014584
- Testing
- Dutasteride
- Where
- 18 sites in Chile, Hong Kong and 3 more
- Volunteers
- 117 people
- Sponsor
- Stiefel, a GSK Company
Androgenetic Alopecia
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
- Trial name
- NCT01885676
- Testing
- PRGF-Endoret, Saline Solution
- Where
- 2 sites in Spain
- Sponsor
- Biotechnology Institute IMASD